Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.3%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.1%.